keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant chemotherapy in breast cancer

keyword
https://www.readbyqxmd.com/read/29452759/feasibility-study-of-weekly-nanoparticle-albumin-bound-paclitaxel-150-mg-m-2-followed-by-fluorouracil-epirubicin-and-cyclophosphamide-therapy-as-neoadjuvant-chemotherapy-for-her2-negative-breast-cancer
#1
Yasuyuki Kojima, Hisanori Kawamoto, Toru Nishikawa, Ryosuke Hayami, Arata Shimo, Ei Haku, Kyoko Akiyama, Koichiro Tsugawa
BACKGROUND: Although several studies have shown efficacy of nanoparticle albumin-bound (nab) paclitaxel use as a neoadjuvant treatment in breast cancer, dosage and schedules were varied or used in combination and the data are still limited for weekly regimens. We evaluated the feasibility of weekly nab-paclitaxel followed by FEC (5-FU [fluorouracil], epirubicin, and cyclophosphamide) treatment feasibility as neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS: Thirty-three patients with no previous chemotherapy were enrolled to receive nab-paclitaxel 150 mg/m 2 the first 3 of 4 weeks (3q4w) followed by FEC as neoadjuvant treatment...
January 11, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29448072/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar-and-trastuzumab-reference-product-in-her2-positive-early-breast-cancer-treated-with-neoadjuvant-adjuvant-treatment-final-safety-immunogenicity-and-survival-results
#2
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, J-H Ahn, S-A Im, T Sarosiek, S Chatterjee, M Z Wojtukiewicz, Y Shparyk, V Moiseyenko, M Bello, V Semiglazov, Y Lee, J Lim
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)...
February 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29445928/efficacy-and-safety-of-trastuzumab-lapatinib-and-paclitaxel-neoadjuvant-treatment-with-or-without-prolonged-exposure-to-anti-her2-therapy-and-with-or-without-hormone-therapy-for-her2-positive-primary-breast-cancer-a-randomised-five-arm-multicentre-open-label
#3
N Masuda, M Toi, N Yamamoto, H Iwata, K Kuroi, H Bando, S Ohtani, T Takano, K Inoue, Y Yanagita, H Kasai, S Morita, T Sakurai, S Ohno
BACKGROUND: Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding optimal duration of treatment and combination impact of endocrine therapy for luminal HER2 disease. METHODS: We designed a randomised phase II, five-arm study to evaluate the efficacy and safety of lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with/without prolongation of anti-HER2 therapy prior to chemotherapy (18 vs...
February 14, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29440915/effects-of-core-needle-biopsy-and-subsequent-neoadjuvant-chemotherapy-on-molecular-alterations-and-outcome-in-breast-cancer
#4
Lingmin Xie, Xiaolei Li, Qinchuan Wang, Jichun Zhou, Jun Shen, Lixi Luo, Yi Lu, Linbo Wang
Objectives: The aim of our study is to evaluate the effect of core needle biopsy (CNB) and subsequent neoadjuvant chemotherapy (NAC) on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth hormone receptor 2 (HER2) and Ki67 in breast cancer, and the associated influencing factors. Materials and methods: In this retrospective cohort study, 143 patients with primary operable breast cancer who received NAC were included. ER, PR, HER2 and Ki67 statuses were compared between pretreatment and posttreatment residual samples...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29435853/do-patients-whose-tumor-achieved-a-pathological-response-relapse-at-specific-sites-a-substudy-of-the-eortc-10994-big-1-00-trial
#5
Kim C Aalders, Nathan Touati, Konstantinos Tryfonidis, Mylène Annonay, Saskia Litiere, Jonas Bergh, Alexandre Bodmer, David A Cameron, Hervé R Bonnefoi
PURPOSE: To determine the sites of first distant relapse in patients with or without pCR following neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. METHODS: We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ...
February 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29434896/intra-arterial-interventional-therapy-for-inoperable-local-advanced-breast-cancer-a-retrospective-study
#6
Jing Ma, Jin Song, Hai Chen, Cibo Fan, Jiaqi Xie, Xiaodong Qi
The aim of the present study was to evaluate the safety and efficacy of intra-arterial interventional therapy (IAIT) in the treatment of inoperable local advanced breast cancer (LABC). A total of 7 patients with pathologically proven inoperable LABC were included in the present study. Patients received 1-4 cycles of IAIT prior to mastectomy and postoperative adjuvant therapy. The safety and clinical outcomes of IAIT were retrospectively analyzed. Between February 2009 to September 2016, 7 patients received IAIT...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29431574/dynamic-diffuse-optical-tomography-for-monitoring-neoadjuvant-chemotherapy-in-patients-with-breast-cancer
#7
Jacqueline E Gunther, Emerson A Lim, Hyun K Kim, Molly Flexman, Mirella Altoé, Jessica A Campbell, Hanina Hibshoosh, Katherine D Crew, Kevin Kalinsky, Dawn L Hershman, Andreas H Hielscher
Purpose To identify dynamic optical imaging features that associate with the degree of pathologic response in patients with breast cancer during neoadjuvant chemotherapy (NAC). Materials and Methods Of 40 patients with breast cancer who participated in a longitudinal study between June 2011 and March 2016, 34 completed the study. There were 13 patients who obtained a pathologic complete response (pCR) and 21 patients who did not obtain a pCR. Imaging data from six subjects were excluded from the study because either the patients dropped out of the study before it was finished or there was an instrumentation malfunction...
February 12, 2018: Radiology
https://www.readbyqxmd.com/read/29429940/review-of-novel-sentinel-lymph-node-biopsy-techniques-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#8
REVIEW
Yeliz Emine Ersoy, Huseyin Kadioglu
Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biopsy proven positive lymph nodes must be reliably excised and examined after NAC to further decrease the false negativity rate of sentinel lymph node (SLN) surgery. The standard method for axillary staging in breast cancer patients even after NAC is SLN biopsy (SLNB) with a radioisotope, blue dye, or both (dual technique)...
January 31, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29428039/rationale-for-mastectomy-after-neoadjuvant-chemotherapy
#9
Lejla Hadzikadic Gusic, Kendall Walsh, Teresa Flippo-Morton, Terry Sarantou, Danielle Boselli, Richard L White
Neoadjuvant chemotherapy (NAC) reduces tumor size, facilitating the use of breast conservation surgery (BCS). However, mastectomy remains the surgical outcome for certain women. The goal of this study was to determine the rationale for mastectomy after NAC, particularly in women eligible for BCS. Retrospective data were reviewed on patients who received NAC between February 2006 and August 2010 at our institution. Demographics and tumor characteristics were compared between patients who received BCS and mastectomy after NAC...
January 1, 2018: American Surgeon
https://www.readbyqxmd.com/read/29423090/efficacy-of-assessing-circulating-cell-free-dna-using-a-simple-fluorescence-assay-in-patients-with-triple-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-a-prospective-observational-study
#10
Kwonoh Park, Miyoung Woo, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jin Roh, Gyungyub Gong, Sung-Bae Kim
This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for early prediction of a pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients with clinical stage II or III TNBC scheduled for neoadjuvant chemotherapy were prospectively enrolled. All patients underwent four cycles of Adriamycin plus cyclophosphamide (AC), followed by four cycles of cisplatin or docetaxel chemotherapy and surgery...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29420367/early-response-assessed-by-contrast-enhanced-ultrasound-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy
#11
Ting Dong
The study was aimed to investigate the role of contrast-enhanced ultrasound (CEUS) in evaluating the response of patients with breast cancer after receiving neoadjuvant chemotherapy (NAC). A systematic search was conducted in PubMed, Spring, Wanfang, and CNKI databases from 1923 to December 2016. Based on fixed effect model or randomized effects model, standardized mean difference (SMD) with its 95% confidence interval (95% CI) was calculated in accordance with heterogeneity analysis. Cochran Q and I tests were used to measure heterogeneity...
February 7, 2018: Ultrasound Quarterly
https://www.readbyqxmd.com/read/29409738/oca2-rs4778137-polymorphism-predicts-survival-of-breast-cancer-patients-receiving-neoadjuvant-chemotherapy
#12
Xiao-Ping Li, Jian-Yun Lan, Dong-Qin Liu, Hang Zhou, Miao-Miao Qian, Wei-Wei Wang, Man Yang
BACKGROUND: Genome-wide association study (GWAS) studies have showed that single nucleotide polymorphisms (SNPs) in OCA2 gene were associated with the survival of breast cancer patients treated with adjuvant chemotherapy. To further explain the association between OCA2 SNPs and breast cancer survival, we investigated the predictive value of rs4778137 located in OCA2 in local advanced breast cancer patients receiving neoadjuvant chemotherapy. PATIENTS AND METHODS: A case-cohort with 150 breast cancer patients was performed to evaluate the effects of the OCA2 rs4778137 on breast cancer survival...
February 1, 2018: Gene
https://www.readbyqxmd.com/read/29396664/single-arm-neoadjuvant-phase-ii-trial-of-pertuzumab-and-trastuzumab-administered-concomitantly-with-weekly-paclitaxel-followed-by-5-fluoruracil-epirubicin-and-cyclophosphamide-fec-for-stage-i-iii-her2-positive-breast-cancer
#13
Julia Foldi, Sarah Mougalian, Andrea Silber, Donald Lannin, Brigid Killelea, Anees Chagpar, Nina Horowitz, Courtney Frederick, Lawrence Rispoli, Trisha Burrello, Maysa Abu-Khalaf, Kert Sabbath, Tara Sanft, Debra S Brandt, Erin W Hofstatter, Christos Hatzis, Michael P DiGiovanna, Lajos Pusztai
PURPOSE: The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are administered concurrently during both the taxane and anthracycline phases of paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) neoadjuvant chemotherapy. METHODS: The pCR rates were assessed separately in hormone receptor (HR) positive and negative cases following Simon's two-stage design, aiming to detect a 20% absolute improvement in pCR rates from 50 to 70 and 70 to 90% in the HR-positive and HR-`negative cohorts, respectively...
February 2, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29396328/dedicated-breast-pet-for-detecting-residual-disease-after-neoadjuvant-chemotherapy-in-operable-breast-cancer-a-prospective-cohort-study
#14
Shinsuke Sasada, Norio Masumoto, Noriko Goda, Keiko Kajitani, Akiko Emi, Takayuki Kadoya, Morihito Okada
PURPOSE: Diagnostic methods to evaluate the response to neoadjuvant chemotherapy (NAC) for breast cancer have not been established. Dedicated breast PET (DbPET) is a high-resolution molecular breast imaging method, and we investigated the capability of DbPET to predict residual primary tumors after NAC compared with whole-body PET (WBPET). METHODS: Forty-five patients (47 tumors) underwent WBPET and ring-type DbPET after NAC, and the tumors were completely resected between January 2016 and March 2017...
January 17, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29394628/-a-case-of-skull-base-metastasis-of-breast-cancer-with-dysphasia-odynophagia-and-dysarthria
#15
Hirotoshi Takahashi, Maya Uno, Kazuya Miyoshi
While skull base metastases from breast cancer are not uncommon, there are relatively few reported cases in the literature. We report a case of skull base metastasis of breast cancer that resulted in dysphasia, odynophagia, and dysarthria. The case involved a woman in her 50 s who was diagnosed with cancer of the right breast(cT4N1M0, cStage III B)at another medical institution 9 years previously and who underwent a partial mastectomy and an axillary lymph node dissection following neoadjuvant chemotherapy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394563/-four-cases-of-occult-breast-cancer-treated-with-breast-conserving-therapy-after-neoadjuvant-chemotherapy
#16
Tetsutaro Miyoshi, Masayuki Shiobara, Kazuo Wakatsuki, Syuka Arai, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihisa Takahashi, Shigeru Yoshioka
We report 4 patients with occult breast cancer(OBC)who underwent breast conserving therapy(BCT)after neoadjuvant chemotherapy(NAC). All patients complained of axillary tumor and were diagnosed by core needle biopsy. Pathological examination of the axillary lymph nodes proved that 3 cases were adenocarcinomas and 1 case was squamous cell carcinoma, but imaging studies could not depict any primary lesions in the breast and other organs. Since distant metastasis was not observed, BCT with axillary lymph node dissection(ALND)was performed after NAC...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394549/-a-long-surviving-case-of-her2-positive-breast-cancer-with-brain-metastasis-treated-through-multidisciplinary-therapy
#17
Takashi Nakakuma, Kana Takahashi, Souichirou Ueno, Yasushi Kondou, Yoshimasa Kosaka, Norihiko Sengoku
We present a case of a 48-year-old woman who visited our hospital due to a lump in her left breast. She was diagnosed with HER2-positive, hormone-positive stage III A breast cancer. The patient underwent trastuzumab-based neoadjuvant chemotherapy and surgery(Bt+Ax). The pathological effect of neoadjuvant chemotherapy was Grade 1b. The patient underwent radiotherapy and was administered hormone therapy and adjuvant trastuzumab. Seven months postsurgery, the patient was taken to the hospital for loss of consciousness...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394544/-prognostic-analysis-of-breast-cancer-patients-who-underwent-neoadjuvant-chemotherapy-using-qol-acd
#18
Yasuhiro Fukui, Shinichiro Kashiwagi, Koji Takada, Wataru Goto, Yuka Asano, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Kosei Hirakawa, Masaichi Ohira
We investigated into association of quality of life(QOL)and prognosis of breast cancer patients who underwent neoadjuvant chemotherapy(NAC). We retrospectively studied 228 patients with breast cancer who were performed NAC during a period between 2007 and 2015. TheQ OL score was measured with"The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs(QOL-ACD)". We evaluate association between QOL score with antitumor effect and prognosis. Changes in the QOL score between before and after NAC were compared as well...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394169/pure-intralymphatic-invasion-in-the-absence-of-stromal-invasion-after-neoadjuvant-therapy-a-rare-pattern-of-residual-breast-carcinoma
#19
Marie-Christine Guilbert, Beth Overmoyer, Susan C Lester
Rarely is intralymphatic/lymph-vascular invasion (LVI) the only residual disease in the breast after neoadjuvant chemotherapy. Only 12 patients have been reported in 2 prior studies. Prognosis was poor, with only 2 patients remaining alive and disease-free. The purpose of this study was to gather more data on this pattern of residual disease. Cases in which LVI was the only residual disease in the breast were retrospectively identified. Eighteen cases were identified including 10 of 669 (1.5%) consecutive surgical cases between 2003 and 2015...
February 1, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29392540/association-of-urinary-and-plasma-dna-in-early-breast-cancer-patients-and-its-links-to-disease-relapse
#20
Z Liu, W Liu
PURPOSE: Identifying patients who are at risk of relapse is a key challenge of primary breast cancer. The current study investigates the utility of urinary DNA in breast cancer management and as a predictor of relapse. This work also compares the sensitivity of plasma DNA with urinary DNA. METHODS: Blood plasma and urine specimens were collected concurrently from 200 breast cancer patients receiving neoadjuvant chemotherapy. Comparison of both plasma and urinary DNA was performed at baseline to determine assay significance...
February 1, 2018: Clinical & Translational Oncology
keyword
keyword
55442
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"